Investors

 

Experience cutting edge cancer treatments with Isoray.

Isoray passionately designs and develops innovative and personalized brachytherapy products that effectively treat many forms of cancer. We believe in pioneering solutions for life beyond your cancer.

 

Documents

Governance

Research Analyst Coverage

Ascendiant Capital Markets
Edward Woo

H.C. Wainwright & Co.
Jason Kolbert

Maxim Group
Jason McCarthy

Do you have questions?

We’ll put you in touch with someone to answer any of your investor related questions.

Our Management Team

 

Breakthroughs in brachytherapy by Cesium Pioneers.

Doctors across the US are using Cesium-131 by Isoray in powerful ways with great outcomes. Check out their work.

The ability to deliver high concentrated radiation treatment in a tightly controlled area at the time of surgery really allows us to customize and individualize cancer treatment for our patients.

Dr. Adam J. Luginbuhl, MD

Otolaryngology/Head & Neck Surgery - Head & Neck Cancers, Thomas Jefferson University Hospital

How is brachytherapy “new again,” 30 years on into Dr. John Sylvester’s career?

Radiation Oncologist Dr. John Sylvester, MD shared a few minutes with us at ABS 2018 discussing recent advancements in prostate brachytherapy and their implications for prostate cancer patients.

Dr. John Sylvester: “Newer does not necessarily mean better.”

Dr. Sylvester discusses how the development of new technology can bring new treatment modalities that are frequently pressed upon patients in spite of brachytherapy’s efficacy and rapid side effect resolution.

Biological effectiveness dose and convenience: Why Cesium-131 is the LDR brachytherapy isotope of choice for Dr. Bradley Prestidge.

Dr. Bradley Prestidge, MD, MS, serves as Regional Medical Director of Radiation Oncology for Bon Secours Medical Group in Norfolk, Va. During the...

Your one-stop shop for the latest in brachytherapy at ASTRO 2018

Capitalizing on the same value ASTRO provides for radiation oncologists to connect with peers in a concentrated way, we invite the entire community to visit the Isoray team at ASTRO 2018.

New long-term data show brachytherapy boost improves freedom from biochemical failure outcomes for T3 high-risk prostate cancer by more than eight percent

In a new study, radiation oncologists find that DR-BT is not only feasible, but also highly effective in men with cT3a and cT3b high-risk prostate cancer.